Table 1.

Regions showing significant bilateral group × session interactions for clustering coefficient

RegionsBaseline1d Abs14d Abs
Chamber controlSucrose SACocaine SAChamber controlSucrose SACocaine SAChamber controlSucrose SACocaine SA
CeA0.27 ± 0.020.33 ± 0.060.35 ± 0.020.29 ± 0.030.47 ± 0.060.43 ± 0.04*0.41 ± 0.050.31 ± 0.020.39 ± 0.06
BaA0.28 ± 0.020.35 ± 0.040.35 ± 0.030.28 ± 0.030.41 ± 0.050.41 ± 0.05*0.36 ± 0.040.30 ± 0.010.31 ± 0.04
NAc0.25 ± 0.040.33 ± 0.060.30 ± 0.030.31 ± 0.050.42 ± 0.050.49 ± 0.08*0.41 ± 0.060.28 ± 0.030.33 ± 0.03
dHPC0.32 ± 0.040.42 ± 0.070.34 ± 0.040.32 ± 0.050.45 ± 0.110.46 ± 0.03*0.41 ± 0.030.38 ± 0.040.31 ± 0.02
VP0.28 ± 0.020.34 ± 0.050.36 ± 0.050.30 ± 0.060.43 ± 0.040.50 ± 0.08*0.42 ± 0.040.31 ± 0.020.35 ± 0.04
GP0.28 ± 0.030.31 ± 0.040.37 ± 0.040.34 ± 0.050.43 ± 0.010.47 ± 0.070.39 ± 0.050.27 ± 0.030.30 ± 0.05
LH0.28 ± 0.020.34 ± 0.030.40 ± 0.030.30 ± 0.020.39 ± 0.050.45 ± 0.05*0.35 ± 0.040.31 ± 0.030.32 ± 0.04
PV Thal0.31 ± 0.020.41 ± 0.050.39 ± 0.050.34 ± 0.050.51 ± 0.040.55 ± 0.07*0.42 ± 0.040.30 ± 0.020.34 ± 0.05
AP Thal0.31 ± 0.010.45 ± 0.060.40 ± 0.040.32 ± 0.040.46 ± 0.080.58 ± 0.06*0.40 ± 0.030.30 ± 0.040.33 ± 0.03
RN Thal0.29 ± 0.040.33 ± 0.070.39 ± 0.040.32 ± 0.050.43 ± 0.050.41 ± 0.040.45 ± 0.060.28 ± 0.040.34 ± 0.05
MD Thal0.35 ± 0.030.42 ± 0.040.33 ± 0.030.32 ± 0.050.41 ± 0.050.48 ± 0.06*0.36 ± 0.030.32 ± 0.020.30 ± 0.02
VL Thal0.32 ± 0.020.35 ± 0.030.38 ± 0.030.32 ± 0.040.45 ± 0.04*0.47 ± 0.05*0.40 ± 0.030.30 ± 0.000.38 ± 0.01
VPM Thal0.27 ± 0.040.35 ± 0.060.35 ± 0.030.32 ± 0.030.57 ± 0.06*0.39 ± 0.08*0.38 ± 0.050.32 ± 0.030.34 ± 0.04
LP Thal0.33 ± 0.020.41 ± 0.080.35 ± 0.040.31 ± 0.030.47 ± 0.10*0.54 ± 0.04*0.37 ± 0.030.26 ± 0.040.31 ± 0.02
Pf Thal0.30 ± 0.030.39 ± 0.050.31 ± 0.030.29 ± 0.040.46 ± 0.01*0.51 ± 0.06*0.42 ± 0.070.32 ± 0.010.34 ± 0.02
LG Thal0.33 ± 0.030.41 ± 0.040.33 ± 0.050.33 ± 0.050.47 ± 0.040.52 ± 0.04*0.40 ± 0.060.33 ± 0.030.37 ± 0.04
PrL0.33 ± 0.020.36 ± 0.050.30 ± 0.020.31 ± 0.050.41 ± 0.020.40 ± 0.030.43 ± 0.060.31 ± 0.020.36 ± 0.04
IL0.30 ± 0.030.28 ± 0.020.30 ± 0.010.31 ± 0.060.49 ± 0.120.43 ± 0.060.43 ± 0.080.28 ± 0.030.32 ± 0.04
M20.29 ± 0.030.28 ± 0.000.39 ± 0.050.29 ± 0.050.33 ± 0.070.46 ± 0.060.50 ± 0.080.31 ± 0.030.36 ± 0.03
S1 jw0.29 ± 0.030.39 ± 0.040.28 ± 0.020.31 ± 0.040.42 ± 0.040.38 ± 0.080.43 ± 0.040.30 ± 0.030.34 ± 0.05
S1 ul0.28 ± 0.020.31 ± 0.010.37 ± 0.050.29 ± 0.030.38 ± 0.050.44 ± 0.07*0.40 ± 0.030.30 ± 0.040.35 ± 0.04
S1 Sh0.29 ± 0.020.36 ± 0.030.33 ± 0.030.33 ± 0.050.44 ± 0.050.49 ± 0.07*0.38 ± 0.040.29 ± 0.020.32 ± 0.04
S20.28 ± 0.030.33 ± 0.020.39 ± 0.050.31 ± 0.050.39 ± 0.060.48 ± 0.05*0.40 ± 0.030.26 ± 0.040.33 ± 0.06

  • Data are shown as the mean ± SEM for sucrose or cocaine SA rats and chamber exposure controls at baseline, 1d Abs, and 14d Abs. CeA, Central amygdala; BaA, basal amygdala; dHPC, dorsal hippocampus; VP, ventral pallidum; GP, globus pallidus; LH, lateral hypothalamus; Thal, thalamus; PV, paraventricular; AP, anteroposterior; RN, reticular nucleus; MD, mediodorsal; VL, ventrolateral; VPM, ventroposteromedial; LP, lateroposterior; Pf, parafascicular; LG, lateral genticulate; PrL, prelimbic; IL, infralimbic; M2, secondary motor; S1, primary somatosensory cortex; jw, jaw region, ul, upper lip; Sh, shoulder; S2, secondary somatosensory cortex. All regions in the table showed significant group × session interactions with a repeated-measures two-factor ANOVA (α < 0.05).

  • Asterisks represent the results of Tukey’s multiple-comparison post hoc test: *difference from chamber exposure controls; **difference between cocaine and sucrose groups.